WO2022075503A1 - 블록킹제, 이를 사용하는 분석 재료의 검출 방법 및 이를 포함하는 분석 재료의 검출 키트 - Google Patents
블록킹제, 이를 사용하는 분석 재료의 검출 방법 및 이를 포함하는 분석 재료의 검출 키트 Download PDFInfo
- Publication number
- WO2022075503A1 WO2022075503A1 PCT/KR2020/013725 KR2020013725W WO2022075503A1 WO 2022075503 A1 WO2022075503 A1 WO 2022075503A1 KR 2020013725 W KR2020013725 W KR 2020013725W WO 2022075503 A1 WO2022075503 A1 WO 2022075503A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blocking
- solution
- blocking agent
- analyte
- minutes
- Prior art date
Links
- 239000002981 blocking agent Substances 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 40
- 239000012491 analyte Substances 0.000 title claims abstract description 37
- -1 polyoxyethylene Polymers 0.000 claims abstract description 45
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 38
- 150000005215 alkyl ethers Chemical class 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 230000000903 blocking effect Effects 0.000 claims description 146
- 239000000463 material Substances 0.000 claims description 31
- 238000002965 ELISA Methods 0.000 claims description 19
- 238000001262 western blot Methods 0.000 claims description 14
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 13
- 238000003018 immunoassay Methods 0.000 claims description 10
- 238000003117 fluorescence-linked immunosorbent assay Methods 0.000 claims description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims description 6
- 238000003127 radioimmunoassay Methods 0.000 claims description 6
- 238000000636 Northern blotting Methods 0.000 claims description 4
- 238000002105 Southern blotting Methods 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 93
- 102000004169 proteins and genes Human genes 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 239000012528 membrane Substances 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 11
- 239000000020 Nitrocellulose Substances 0.000 description 11
- 239000007853 buffer solution Substances 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 229920001220 nitrocellulos Polymers 0.000 description 11
- 239000005018 casein Substances 0.000 description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 9
- 235000021240 caseins Nutrition 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000009870 specific binding Effects 0.000 description 8
- 230000009871 nonspecific binding Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 235000013861 fat-free Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 101150006407 NRF1 gene Proteins 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
Definitions
- the present invention relates to a blocking agent, a method for detecting an analyte using the same, and a kit for detecting an analyte containing the same.
- Immunochemical methods are widely used to analyze the presence or absence of proteins such as antigens and antibodies, or to analyze the content of these proteins.
- Western blot and ELISA analysis methods are used. Specifically, the protein is moved by a method such as SDS PAGE, and then the transferred protein is transferred to a nitrocellulose or PVDF membrane, and then the primary antibody and the secondary antibody are sequentially reacted to measure the presence or content of the protein. is composed
- the blocking process is a process that prevents contaminants other than the protein to be analyzed or binding between the measurement device and the primary antibody.
- the blocking process is an essential process to increase the analytical reliability and analytical sensitivity of the analyte material.
- a blocking agent which is one or more compounds of non-fat dry milk (skim milk powder), casein, bovine serum albumin, and PVP (polyvinylpyrrolidone), is dissolved in a predetermined buffer, and then the membrane This is done by processing in
- the conventional blocking agent takes a long time to analyze the analyte material because the reaction time is long from 30 minutes to 1 hour, and it cannot completely prevent non-specific binding, which may interfere with the specific binding of the analyte material.
- organic substances such as non-fat dry milk, casein, and bovine serum albumin among existing blocking agents should be stored at about 4° C. when stored as an organic substance, and the storage period is also short, about 1 week. There is a lot of risk of contamination by breeding.
- the flow of the existing blocking agent is stopped as a blocking solution, it is hardened in the nozzle in the equipment, so it is difficult to use it in an automated device.
- An object of the present invention is to provide a blocking agent capable of shortening the analysis time of the analyte material by reducing the blocking reaction time.
- Another object of the present invention is to provide a blocking agent that can be stored at room temperature for a long time and does not cause contamination with bacteria.
- Another object of the present invention is to provide a blocking agent that completely blocks non-specific binding to an antibody and does not affect specific binding between antigen-antibody, thereby increasing analysis reliability.
- Another object of the present invention is to provide a blocking agent that is easy to automate analysis because it does not solidify even in a solution state.
- One aspect of the present invention is a blocking agent.
- the blocking agent includes polyoxyethylene alkyl ether or a salt thereof.
- the polyoxyethylene alkyl ether is polyoxyethylene lauryl ether; polyoxyethylene cetyl ether; one or more of polyoxyethylene oleyl ethers.
- the polyoxyethylene alkyl ether may be polyoxyethylene oleyl ether.
- Another aspect of the invention is a method for detecting an analyte.
- a method for detecting an analyte includes the step of using the blocking agent of the present invention.
- the blocking process may include treating a blocking solution containing 0.01% to 5% of the blocking agent at 20°C to 30°C for 3 minutes to 20 minutes.
- the method of detecting the assay material is an enzyme-linked immunosorbent assay (ELISA), a fluorescence-linked immunosorbent assay (FLISA), a fluorescent enzyme-linked immunosorbent assay Fluorescent enzyme-linked immunosorbent assay (FELISA), fluorescence immunoassay (FLIA), Chemiluminescence immunoassay (CLIA), Enzyme-Linked Immunosorbent Spot assay (ELISPOT), It may include one or more of an enzyme immunoassay (EIA), a radioimmunoassay (RIA), a Western Blot, a Southern Blot, and a Northern Blot.
- ELISA enzyme-linked immunosorbent assay
- FLISA fluorescence-linked immunosorbent assay
- FELISA fluorescent enzyme-linked immunosorbent assay
- FLIA fluorescence immunoassay
- CLIA Chemiluminescence immunoassay
- ELISPOT Enzyme-Linked Immunosorbent Spot assay
- EIA enzyme
- the method of detecting the analyte may be based on an immune response.
- Another aspect of the present invention is the detection of an analyte comprising the blocking agent of the present invention.
- the present invention provides a blocking agent capable of shortening the analysis time of the analyte material by reducing the blocking reaction time.
- the present invention provides a blocking agent that can be stored at room temperature for a long period of time and does not cause contamination with bacteria.
- the present invention provides a blocking agent that completely blocks non-specific binding to an antibody and has no effect on specific binding between antigen-antibody, thereby enhancing analysis reliability.
- the present invention provides a blocking agent that is easy to automate analysis because it does not solidify even in a solution state.
- FIG. 7 is an evaluation result in Experimental Example 6.
- the solid line is the blocking solution I
- the dotted line is the blocking solution II
- the dashed-dotted line is the result of the blocking solution VI.
- the analyte is generally analyzed by specific binding between detection materials.
- the analyte material may be an antigen, a protein including an antibody, and the like, or a nucleic acid including DNA, RNA, a probe, a primer, and the like.
- a blocking process is essential to prevent non-specific binding of the detection material to contaminant materials other than the analyte material or to prevent binding to the surface of the device. The blocking process is generally performed prior to dosing of the detection material.
- the present invention provides a blocking agent that can shorten the analysis time of the analyte material by reducing the blocking reaction time, can be stored at room temperature for a long period of time, and does not cause contamination with bacteria.
- the present invention provides a blocking agent that completely blocks non-specific binding to contaminant materials other than the analyte material and does not affect the specific binding between the analyte material and the detection material, thereby increasing the analysis reliability.
- the present invention provides a blocking agent capable of realizing automation of analysis because it is not solidified even in a solution state, so it is easy to automate analysis.
- the blocking agent according to an embodiment of the present invention is used in an analysis method by specific binding of a biological analysis material, and polyoxyethylene alkyl ether (polyoxyethylene alkyl ether).
- the analysis method is described in more detail below.
- Polyoxyethylene alkyl ethers can shorten the reaction and/or coagulation time of about 3 minutes to about 5 minutes, thereby reducing the blocking reaction time, thereby shortening the analysis time of the analyte material.
- Polyoxyethylene alkyl ether does not have an amine group, so it can be stored in solution for a long period of time, for example, at room temperature for more than 6 months, so there is no possibility of contamination with bacteria.
- Polyoxyethylene alkyl ether completely blocks non-specific binding to contaminant materials other than the analyte material, and does not affect the specific binding between the analyte material and the detection material, thereby enhancing analysis reliability.
- polyoxyethylene alkyl ether may be represented by the following formula (1):
- n is an integer from 2 to 100;
- R is a straight-chain or branched-chain alkyl group having 10 to 20 carbon atoms or a straight-chain or branched-chain alkenyl group having 10 to 20 carbon atoms
- n may be specifically 10 to 100. Within the above range, it can be easily used as a blocking agent in the analysis of the antigen-antibody, and the reliability of the analysis of the antigen-antibody can be increased.
- R is specifically a linear or branched alkyl group having 10 to 18 carbon atoms or an alkenyl group having 10 to 18 carbon atoms, more specifically a straight or branched chain alkenyl group having 12 to 18 carbon atoms can
- R may be an oleyl group, a lauryl group, or a cetyl group. Most preferably R may be an oleyl group.
- the polyoxyethylene alkyl ether is polyoxyethylene lauryl ether, including polyoxyethylene (4) lauryl ether and the like; polyoxyethylene cetyl ether including polyoxyethylene (2) cetyl ether, polyoxyethylene (20) cetyl ether, and the like; polyoxyethylene (2) oleyl ether, polyoxyethylene (10) oleyl ether, polyoxyethylene (20) oleyl ether, and the like.
- the polyoxyethylene alkyl ether may be polyoxyethylene oleyl ether.
- the polyoxyethylene alkyl ether may have an average molecular weight of 300 to 1200, specifically 700 to 1200, more specifically 1000 to 1200. In the above range, it may be easy to use as a blocking agent.
- Polyoxyethylene alkyl ethers can be prepared by conventional methods known to those skilled in the art or used as commercially available products.
- the blocking agents of the present invention include salts of polyoxyethylene alkyl ethers.
- Salts of polyoxyethylene alkyl ethers may include salts prepared through acid-base reaction of polyoxyethylene alkyl ethers. Examples include, but are not limited to, sulfonates of polyoxyethylene alkyl ethers, phosphonates of polyoxyethylene alkyl ethers, and the like.
- the method for detecting an analyte according to an embodiment of the present invention includes performing a blocking process using the blocking agent according to an embodiment of the present invention.
- the method for detecting an analyte according to an embodiment of the present invention may be used to detect a biological analyte.
- the biological assay material may include, but is not limited to, proteins including antigens, antibodies, and the like, nucleic acids including DNA, RNA, probes, primers, and the like.
- the blocking process may include preparing a blocking solution in which the blocking agent of the present invention is dissolved in a predetermined buffer, and treating the film and/or substrate containing the analyte material with the blocking solution.
- the treatment may include treating in a blocking solution at 20° C. to 30° C., specifically, 20° C. to 25° C. for 3 minutes to 20 minutes, specifically 3 minutes to 10 minutes, and more specifically, treatment for 3 minutes to 5 minutes.
- a blocking solution at 20° C. to 30° C., specifically, 20° C. to 25° C. for 3 minutes to 20 minutes, specifically 3 minutes to 10 minutes, and more specifically, treatment for 3 minutes to 5 minutes.
- the blocking agent of the present invention can obtain the effects of the present invention described above.
- the blocking agent in the blocking solution may be included in an amount of 0.01% to 5%, specifically 0.01% to 1%. In the above range, it is possible to properly produce a blocking effect, and to lower the influence due to the remaining of the unreacted blocking agent.
- the buffer in the blocking solution may be used by employing a conventional type known to those skilled in the art.
- the buffer may include, but is not limited to, one or more of a TBST buffer and a PBS buffer.
- the detection method of the analysis material is a detection method for the purpose of sensitivity and specificity based on an immune response, and automation of rapid diagnostic kits including cellulose-based diagnostic kits, protein chips, chemiluminescence immunoassay, etc. It can be applied to methods requiring blocking in diagnostic equipment.
- the method for detecting the analyte may specifically include an immunochemical analysis method.
- the detection method of the assay material may be an enzyme-linked immunosorbent assay (ELISA), a fluorescence-linked immunosorbent assay (FLISA), or a fluorescent enzyme-linked immunosorbent assay.
- fluorescent enzyme-linked immunosorbent assay, FELISA fluorescence immunoassay
- FLIA fluorescence immunoassay
- CLIA chemiluminescence immunoassay
- ELISPOT Enzyme-Linked Immunosorbent Spot assay
- EIA enzyme immunoassay
- RIA radioimmunoassay
- the kit for detecting an analyte according to an embodiment of the present invention includes the blocking agent according to an embodiment of the present invention.
- the detection kit of the present invention may include a kit to which the above detection method is applied.
- 3T3L1 cells Korea Cell Line Bank, preadipocytes
- 1uM insulin and 1uM Dexametasone for 5 days to differentiate them into adipocytes
- Cell Lysis buffer (20mM Tris-HCl (pH7.4), 1mM EDTA, 140mM NACl, 1 % NP-40, 1mM Na3VO4, 50mM NaF and 10ug/ml aprotinin) was used to dissolve differentiated 3T3L1, and a solution containing Nrf1, a protein to be isolated, was obtained.
- 12% SDS PAGE was prepared by Laemmli method, and the protein-containing solution was electrophoresed. An electric charge was applied to the gel in which the protein was electrophoresed and transferred to a nitrocellulose membrane by a semi-dry transfer process. Blocking treatment was performed by immersing the nitrocellulose membrane in the blocking solution of Table 1 under the conditions of Table 1 below. Then, the primary antibody Nrf1 (Abcam, cat#:ab34682) was treated and after 1 hour reaction, it was washed 3 times over 5 minutes with PBST buffer.
- Nrf1 Abcam, cat#:ab34682
- Blocking Solution I Blocking Solution II Blocking Solution III total amount of protein ( ⁇ g) 20 15 10 20 15 10 20 15 10 blocking temperature (°C) 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 blocking time (minute) 60 60 60 10 10 10 10 10 10 Results in Figure 1 A B C D E F G H I
- the blocking solution III containing the blocking agent of the present invention can completely block in 10 minutes, so it can be seen that the band of the target protein is darkened.
- the blocking agent of the present invention has an excellent blocking effect even at a concentration of 0.2%.
- blocking solution I it can be seen that a band of the target protein was produced by blocking for 1 hour.
- blocking solution II showed a blocking effect in 10 minutes, but blocking was not perfect, so it can be seen that a signal was strongly generated in the background.
- Blocking Solution I Blocking Solution II Blocking Solution III Total amount of protein ( ⁇ g) 10 5 10 5 10 5 Blocking temperature (°C) 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 Blocking time (minutes) 60 60 10 10 10 10 Film exposure time (seconds) 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30
- Blocking Solution I Blocking Solution II Blocking Solution III Total amount of protein ( ⁇ g) 10 5 10 5 10 5 Blocking temperature (°C) 25 25 25 25 25 25 25 25 25 25 25 Blocking time (minutes) 60 60 10 10 10 10 Film exposure time (seconds) 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180
- the blocking solution III containing the blocking agent of the present invention did not lower the blocking efficiency even if overexposed to the film, and a perfect blocking effect was obtained in 10 minutes.
- blocking solution I was blocked, but the antigen-antibody reaction was poor.
- Blocking solution II showed a strong background when overexposed, resulting in poor blocking efficiency.
- Blocking Solution IV blocking solution Blocking Solution V Blocking Solution III Total amount of protein ( ⁇ g) 20 15 10 20 15 10 20 15 10 Blocking temperature (°C) 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 Blocking time (minutes) 60 60 60 60 60 60 10 10 10 Results in Figure 4 A B C D E F G H I
- the blocking solution III containing the blocking agent of the present invention increases the specific binding between antigens and antibodies and has a perfect blocking effect even after blocking for 10 minutes with a 0.2% solution.
- the blocking solution IV and the blocking solution V contain 1 to 5% and have a blocking effect for 1 hour.
- Blocking efficiency was evaluated using only the HRP-conjugated antibody as the secondary antibody after blocking the nitrocellulose membrane under the blocking conditions in Table 5 by performing dot blot.
- the nitrocellulose membrane was cut into rounds with a diameter of 1 cm, it was immersed in the blocking solution shown in Table 5 below for 10 minutes. Then, the nitrocellulose membrane was washed 3 times with PBST solution for 5 minutes. Secondary antibody HRP-conjugated Ab (Jackson immuno, Cat#: 115-035-003) was reacted for 30 minutes and washed 3 times for 5 minutes. Thereafter, the blocking effect was evaluated by confirming whether the secondary antibody binds to the nitrocellulose membrane by ECL reaction in the dark.
- the blocking solution shown in Table 5 below for 10 minutes. Then, the nitrocellulose membrane was washed 3 times with PBST solution for 5 minutes. Secondary antibody HRP-conjugated Ab (Jackson immuno, Cat#: 115-035-003) was reacted for 30 minutes and washed 3 times for 5 minutes. Thereafter, the blocking effect was evaluated by confirming whether the secondary antibody binds to the nitrocellulose membrane by ECL reaction in the dark.
- Total amount of protein ( ⁇ g) 20 20 20 20 20 20 20 20 20 Blocking temperature (°C) 25 25 25 25 25 25 25 25 25 25 Blocking time (minutes) 10 10 10 10 10 10 Results in Figure 5 One 2 3 4 5 6
- the blocking solution (6) containing the blocking agent of the present invention exhibited a blocking effect even in the process for 10 minutes. However, it can be seen that the blocking solutions (1) to (5) have no blocking effect in the process for 10 minutes.
- BSA vitamin D manufactured in-house, 4°C, O/N
- Vitamine D mAb manufactured in-house, concentration changed from 0 to 250ng/ml
- Table 6 ELISA analysis under the conditions. The ELISA method was performed as follows.
- BSA-Vitamin D was diluted with PBS in a 96-well ELISA plate, and the solution was immersed so that 100ng per well was put, and then left at room temperature for 1 hour and washed three times with PBST solution.
- the 96-well plate was immersed in the blocking solution of Table 6 under the conditions shown in Table 6 to perform blocking treatment.
- the primary antibody Vitamin D mAb was treated and after 1 hour reaction, it was washed 3 times over 5 minutes with PBST buffer.
- the plate was reacted with the secondary antibody HRP-conjugated Ab (Jackson immuno, Cat#: 115-035-003) for 30 minutes, washed 3 times in 5 minutes, reacted with TMB solution for 3 minutes, and then using an ELISA reader Thus, the results were confirmed at a wavelength of 450 nm.
- the blocking solution VI containing the blocking agent of the present invention showed a perfect blocking effect in 10 minutes with a 0.02% solution, and increased sensitivity by 30% or more due to excellent antigen-antibody binding.
- Blocking was performed by varying the blocking time to 0 min, 1 min, 3 min, 5 min, 10 min, and 30 min as shown in Table 7 below.
- Other experimental methods were performed in the same manner as in Experimental Example 5. The results are shown in Table 7 and FIG. 7 below.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
블록킹 용액 I | 블록킹 용액 II | 블록킹 용액 III | |||||||
단백질 총량 (㎍) |
20 | 15 | 10 | 20 | 15 | 10 | 20 | 15 | 10 |
블록킹 온도 (℃) |
25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
블록킹 시간 (분) |
60 | 60 | 60 | 10 | 10 | 10 | 10 | 10 | 10 |
도 1에서의 결과 | A | B | C | D | E | F | G | H | I |
블록킹 용액 I | 블록킹 용액 II |
블록킹 용액 III |
||||
단백질 총량(㎍) | 10 | 5 | 10 | 5 | 10 | 5 |
블록킹 온도(℃) | 25 | 25 | 25 | 25 | 25 | 25 |
블록킹 시간(분) | 60 | 60 | 10 | 10 | 10 | 10 |
필름 노출 시간(초) | 30 | 30 | 30 | 30 | 30 | 30 |
도 2에서의 결과 | A | B | C | D | E | F |
블록킹 용액 I |
블록킹 용액 II |
블록킹 용액 III |
||||
단백질 총량(㎍) | 10 | 5 | 10 | 5 | 10 | 5 |
블록킹 온도(℃) | 25 | 25 | 25 | 25 | 25 | 25 |
블록킹 시간(분) | 60 | 60 | 10 | 10 | 10 | 10 |
필름 노출 시간(초) | 180 | 180 | 180 | 180 | 180 | 180 |
도 3에서의 결과 | A | B | C | D | E | F |
블록킹 용액 IV | 블록킹 용액 V | 블록킹 용액 III | |||||||
단백질 총량(㎍) | 20 | 15 | 10 | 20 | 15 | 10 | 20 | 15 | 10 |
블록킹 온도(℃) | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
블록킹 시간(분) | 60 | 60 | 60 | 60 | 60 | 60 | 10 | 10 | 10 |
도 4에서의 결과 | A | B | C | D | E | F | G | H | I |
블록킹 용액(1) |
블록킹 용액(2) |
블록킹 용액(3) |
블록킹 용액(4) |
블록킹 용액(5) |
블록킹 용액(6) |
|
단백질 총량(㎍) | 20 | 20 | 20 | 20 | 20 | 20 |
블록킹 온도(℃) | 25 | 25 | 25 | 25 | 25 | 25 |
블록킹 시간(분) | 10 | 10 | 10 | 10 | 10 | 10 |
도 5에서의 결과 | 1 | 2 | 3 | 4 | 5 | 6 |
블록킹 용액 I | 블록킹 용액 II | 블록킹 용액 VI | |
블록킹 온도(℃) | 25 | 25 | 25 |
블록킹 시간(분) | 60 | 5 | 5 |
항체 농도 | |||
0 ng/ml | 0.0485 | 0.0515 | 0.0484 |
10 ng/ml | 0.4139 | 0.4323 | 0.4565 |
50 ng/ml | 0.5632 | 0.6023 | 0.7326 |
250 ng/ml | 0.557 | 0.6305 | 0.9141 |
블록킹 용액 I | 블록킹 용액 II | 블록킹 용액 VI | |
블록킹 온도(℃) | 25 | 25 | 25 |
블록킹 시간(분) | 60 | 5 | 5 |
블록킹 시간 | |||
30분 | 0.0496 | 0.0551 | 0.0481 |
10분 | 0.0789 | 0.0512 | 0.0473 |
5분 | 0.1945 | 0.0998 | 0.0501 |
3분 | 0.5544 | 0.3622 | 0.0553 |
1분 | 0.9956 | 0.7489 | 0.1492 |
no block | 1.1207 | 1.0987 | 1.0784 |
Claims (8)
- 폴리옥시에틸렌 알킬 에테르 또는 그의 염을 포함하는 것인, 블록킹제.
- 제1항에 있어서, 상기 폴리옥시에틸렌 알킬 에테르는 폴리옥시에틸렌 라우릴 에테르; 폴리옥시에틸렌 세틸 에테르; 폴리옥시에틸렌 올레일 에테르 중 1종 이상을 포함하는 것인, 블록킹제.
- 제1항에 있어서, 상기 폴리옥시에틸렌 알킬 에테르는 폴리옥시에틸렌 올레일 에테르인 것인, 블록킹제.
- 제1항 내지 제3항 중 어느 한 항의 블록킹제를 사용하여 블록킹 공정을 수행하는 단계를 포함하는 것인, 분석 재료의 검출 방법.
- 제4항에 있어서, 상기 블록킹 공정은 상기 블록킹제를 0.01% 내지 5% 포함하는 블록킹 용액을 20℃ 내지 30℃에서 3분 내지 20분 동안 처리하는 것을 포함하는 것인, 분석 재료의 검출 방법.
- 제4항에 있어서, 상기 분석 재료의 검출 방법은 효소-결합 면역 흡착 검사(enzyme-linked immunosorbent assay, ELISA), 형광-결합 면역 흡착 검사(fluorescence-linked immunosorbent assay, FLISA), 형광 효소-결합 면역 흡착 검사(fluorescent enzyme-linked immunosorbent assay, FELISA), 형광 면역 검사(fluorescence immunoassay, FLIA), 화학 발광 면역 검사 (Chemiluminescence immunoassay, CLIA), 효소 결합 면역 흡착 스폿 검사(Enzyme-Linked Immunosorbent Spot assay, ELISPOT), 효소 면역 검사(enzyme immunoassay, EIA), 방사성 면역 검사(radioimmunoassay, RIA), 웨스턴 블롯(Western Blot), 서던 블롯(Southern Blot) 및 노던 블롯(Northern Blot) 중 1종 이상을 포함하는 것인, 분석 재료의 검출 방법.
- 제4항에 있어서, 상기 분석 재료의 검출 방법은 면역 반응에 기초한 것인, 분석 재료의 검출 방법.
- 제1항 내지 제3항 중 어느 한 항의 블록킹제를 포함하는 것인, 분석 재료의 검출 키트.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2020/013725 WO2022075503A1 (ko) | 2020-10-08 | 2020-10-08 | 블록킹제, 이를 사용하는 분석 재료의 검출 방법 및 이를 포함하는 분석 재료의 검출 키트 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2020/013725 WO2022075503A1 (ko) | 2020-10-08 | 2020-10-08 | 블록킹제, 이를 사용하는 분석 재료의 검출 방법 및 이를 포함하는 분석 재료의 검출 키트 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022075503A1 true WO2022075503A1 (ko) | 2022-04-14 |
Family
ID=81126574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/013725 WO2022075503A1 (ko) | 2020-10-08 | 2020-10-08 | 블록킹제, 이를 사용하는 분석 재료의 검출 방법 및 이를 포함하는 분석 재료의 검출 키트 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022075503A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160051817A (ko) * | 2013-09-10 | 2016-05-11 | 덴카 세이켄 가부시키가이샤 | 인플루엔자 바이러스의 면역 측정에 있어서의 검체 처리 방법 및 면역 측정법 |
JP2016075645A (ja) * | 2014-10-09 | 2016-05-12 | デンカ生研株式会社 | 免疫分析方法及び試薬 |
KR20180123561A (ko) * | 2016-03-31 | 2018-11-16 | 세키스이 메디칼 가부시키가이샤 | 간이 면역 측정을 이용한 암 태아성 피브로넥틴의 검출 방법 |
JP2019053060A (ja) * | 2017-09-15 | 2019-04-04 | 富士レビオ株式会社 | B型肝炎ウイルスコア抗体の免疫測定方法 |
JP2019178932A (ja) * | 2018-03-30 | 2019-10-17 | シスメックス株式会社 | リポタンパク質の取り込み能を測定する方法及び試薬 |
-
2020
- 2020-10-08 WO PCT/KR2020/013725 patent/WO2022075503A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160051817A (ko) * | 2013-09-10 | 2016-05-11 | 덴카 세이켄 가부시키가이샤 | 인플루엔자 바이러스의 면역 측정에 있어서의 검체 처리 방법 및 면역 측정법 |
JP2016075645A (ja) * | 2014-10-09 | 2016-05-12 | デンカ生研株式会社 | 免疫分析方法及び試薬 |
KR20180123561A (ko) * | 2016-03-31 | 2018-11-16 | 세키스이 메디칼 가부시키가이샤 | 간이 면역 측정을 이용한 암 태아성 피브로넥틴의 검출 방법 |
JP2019053060A (ja) * | 2017-09-15 | 2019-04-04 | 富士レビオ株式会社 | B型肝炎ウイルスコア抗体の免疫測定方法 |
JP2019178932A (ja) * | 2018-03-30 | 2019-10-17 | シスメックス株式会社 | リポタンパク質の取り込み能を測定する方法及び試薬 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014196803A1 (en) | A strip for rapid testing having a variable control line and a diagnosis kit using the same | |
WO2013081363A1 (ko) | 전위차분석법을 이용한 당화헤모글로빈 측정용 바이오센서 | |
WO2020197305A1 (ko) | 표면-증강 라만 산란 기반의 표적 물질 검출용 기판의 제조방법, 이에 따른 표적 물질 검출용 기판 및 이를 이용한 표적 물질 검출 방법 | |
WO2016036145A1 (ko) | 노로바이러스 검출 센서, 및 이를 이용하는 전기화학적 센싱방법 | |
WO2017039356A1 (ko) | 전기화학적 검출방법에 의한 알레르겐 검출 장치 | |
EP3167276B1 (en) | Contact imager | |
WO2022075503A1 (ko) | 블록킹제, 이를 사용하는 분석 재료의 검출 방법 및 이를 포함하는 분석 재료의 검출 키트 | |
WO2019235836A1 (ko) | 신장질환 조기 진단용 바이오마커 피루브산 키나아제 m2 (pkm2) 및 이의 이용 | |
WO2019039817A9 (ko) | 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법 | |
WO2018084337A1 (ko) | 당화혈색소 비율의 측정 방법 | |
WO2020171346A1 (ko) | 자가항체-항원 결합체를 이용한 폐암 진단용 면역학적 조성물, 이를 사용한 폐암 진단 방법 및 이를 포함하는 폐암 진단용 키트 | |
WO2018004254A1 (ko) | 미세먼지 노출 여부 확인용 바이오마커 및 이를 이용하는 확인방법 | |
AU2021104366A4 (en) | KIT FOR DETECTING DUST MITE COMPONENT-SPECIFIC IMMUNOGLOBULIN E (sIgE) | |
WO2022075773A1 (ko) | 췌장암 진단용 바이오마커 및 이의 용도 | |
JP3115609B2 (ja) | ペルオキシダーゼ活性のアッセイ | |
WO2021145580A1 (ko) | 화학물질 검출 장치 및 화학물질 검출 방법 | |
WO2023146245A1 (ko) | 바이오마커를 이용한 결핵 진단용 조성물, 이를 이용한 결핵 진단방법 및 키트 | |
WO2023282728A1 (en) | Lipid blocking agents for analyte detection | |
WO2017131270A1 (ko) | 나노포어를 이용한 단백질-단백질 상호작용 저해제 스크리닝 방법 | |
Dobado-Berrios et al. | Application of an optimized immunostaining technique to evaluate the heterogeneous secretory response from porcine somatotropes by cell blotting. | |
US4921791A (en) | Method for measuring specific component using peroxidase enzyme reaction | |
WO2020046069A1 (ko) | 펩신에 의해 특이적으로 분해되는 펩타이드 및 이를 포함하는 역류성 인후두염 진단용 키트 | |
WO2018143531A1 (ko) | 단백질의 번역후 변형 모니터링 방법 | |
WO2019013530A9 (ko) | 진단 키트, 진단 방법 및 진단 장치 | |
WO2011129483A1 (ko) | 폐암 진단용 Xage-1d 마커 및 이를 이용한 진단 키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20956818 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20956818 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20956818 Country of ref document: EP Kind code of ref document: A1 |